Evidence Explorer / MS-N216 / Unsupported cure claims and safety / Appraised November 2, 2026
Cancell and related products sold as Cantron or Protocel are mixtures of common chemicals promoted for cancer and other diseases. No peer-reviewed human or animal study demonstrates that they are safe or effective for cancer, and U.S. distribution has been subject to a permanent injunction.
Evidence at a glance
- Aliases: Cancell, Cantron, Protocel, Entelev, Jim’s Juice and related formulations.
- Composition: exact composition is uncertain and products may not be equivalent.
- Human evidence: no peer-reviewed clinical trial; claims rest on testimonials and anecdotal reports.
- Regulatory context: not FDA approved for treating disease; permanent injunction against distribution.
- Evidence label: unsupported cancer-treatment claim with unknown product consistency and incomplete safety evidence.
What was studied
NCI’s PDQ review found no published peer-reviewed human study and no qualifying evidence analysis. Manufacturers have claimed high response rates, but those numbers were not supported by verifiable clinical data.
NCI laboratory testing did not find enough activity to justify further investigation. A chemical mixture or proposed electrical or vibrational mechanism does not establish a clinical anticancer effect.
What this evidence cannot establish
Testimonials cannot verify the cancer diagnosis, concurrent treatment, objective response, follow-up or survival. There is no evidence that these products shrink tumors, prevent recurrence or extend life.
Because composition and manufacturing vary, the absence of reported harm in promotional accounts cannot be generalized to products sold under related names.
Practical safety context
Manufacturer reports cited by NCI include fatigue and nausea, with diarrhea after excess intake, but systematic adverse-event data are absent. Unknown composition adds risks of contamination, dosing error and drug interactions.
Advice to avoid vitamins or conventional treatment while using the product is not evidence-based and could worsen nutrition or delay effective care.
Questions for the care team
- What independent laboratory verifies the exact ingredients and batch?
- Where are the peer-reviewed human outcome data?
- Would using the product delay treatment, symptom control or nutrition support?
Sources
Source note: The NCI health-professional PDQ was checked. It notes that the summary is retained for reference because no strong new research has emerged. No peer-reviewed human study qualifying for efficacy appraisal was identified as of November 2, 2026.
This record is educational. Cancell, Cantron and Protocel are not evidence-based cancer treatments and should not replace oncology care.
